Log in to save to my catalogue

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty l...

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty l...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2581965856

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

About this item

Full title

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2021-10, Vol.27 (10), p.1836-1848

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with...

Alternative Titles

Full title

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2581965856

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2581965856

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-021-01489-1

How to access this item